Harbor Capital Advisors Inc. Sells 29,990 Shares of Exact Sciences Corporation $EXAS

Harbor Capital Advisors Inc. decreased its position in Exact Sciences Corporation (NASDAQ:EXAS) by 61.6% in the third quarter, Holdings Channel.com reports. The firm owned 18,705 shares of the medical research company’s stock after selling 29,990 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Exact Sciences were worth $1,023,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. SVB Wealth LLC bought a new stake in Exact Sciences during the first quarter worth about $30,000. True Wealth Design LLC lifted its holdings in shares of Exact Sciences by 951.8% during the second quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 533 shares in the last quarter. Country Trust Bank purchased a new stake in shares of Exact Sciences during the second quarter valued at $32,000. Bessemer Group Inc. increased its holdings in Exact Sciences by 1,980.6% in the 2nd quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock worth $34,000 after buying an additional 614 shares in the last quarter. Finally, Bayforest Capital Ltd lifted its stake in Exact Sciences by 95.8% during the 1st quarter. Bayforest Capital Ltd now owns 926 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 453 shares during the period. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Trading Up 0.0%

EXAS opened at $101.57 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.44 and a current ratio of 2.72. The stock’s 50 day moving average price is $85.45 and its 200-day moving average price is $63.42. Exact Sciences Corporation has a one year low of $38.81 and a one year high of $102.66. The stock has a market cap of $19.24 billion, a price-to-earnings ratio of -19.09, a P/E/G ratio of 12.53 and a beta of 1.42.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.11. The company had revenue of $850.74 million during the quarter, compared to analysts’ expectations of $810.42 million. Exact Sciences had a positive return on equity of 1.67% and a negative net margin of 32.01%.Exact Sciences’s revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.21) EPS. On average, equities analysts forecast that Exact Sciences Corporation will post -0.58 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on EXAS. Cowen cut Exact Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Guggenheim downgraded shares of Exact Sciences from a “buy” rating to a “neutral” rating in a research report on Thursday, November 20th. BTIG Research cut shares of Exact Sciences from a “buy” rating to a “neutral” rating in a research note on Thursday, November 20th. Wall Street Zen downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Leerink Partnrs cut shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, nineteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Exact Sciences presently has an average rating of “Hold” and a consensus price target of $85.00.

Insider Buying and Selling at Exact Sciences

In other news, EVP Brian Baranick sold 2,858 shares of the business’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total value of $200,288.64. Following the completion of the sale, the executive vice president owned 22,368 shares in the company, valued at approximately $1,567,549.44. The trade was a 11.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James Edward Doyle sold 2,000 shares of the firm’s stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the sale, the director directly owned 57,962 shares in the company, valued at approximately $3,477,720. The trade was a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 9,858 shares of company stock valued at $695,289. Company insiders own 1.20% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.